Ripretinib free base Datasheet DC Chemicals

Description	Ripretinib, also known as DCC-2618, is a potent, orally active and selective KIT/PDGFR inhibitor with potential antineoplastic activity. DCC-2618 targets and binds to both wild-type and mutant forms of KIT and PDGFRa specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. In May 2020, FDA Approves Qinlock (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Cat.No	DC75654
Name	Ripretinib free base

Chemical Properties

CAS	1442472-39-0
Formula	C24H21BRFN5O2
MW	510.37
Storage	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

References

Return Policy

If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.

Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.

Tel: +86-21-58447131
Fax: +86-21-61642470

Email:
sales@dcchemicals.com
order@dcchemicals.com

Website:
www.dcchemicals.com